Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd (HKG: 6922) has announced receiving endorsement from the National Medical Products Administration (NMPA) to market its malignant stenosis cryoablation system in China. This innovative technology represents a significant advancement in the treatment of malignant airway tumors.
Innovative Cryoablation Technology
The malignant stenosis cryoablation system, developed in-house by Cryofocus Medtech, is designed to ablate malignant airway tumor tissue and reduce the frequency of airway restenosis. The system utilizes ultra-low temperatures generated by the cryoablation process to destroy tumor cells in the tracheal cavity and cavity wall.
Mechanism and Benefits
During the surgical process, the system first applies ultra-low temperatures to freeze tumor cells, followed by rewarming to further destroy the cells. This cycle of freezing and thawing ensures more thorough ablation of malignant tumors over a larger range. Cryoablation balloons enable the treatment to reach areas that may be difficult to access with traditional methods, potentially delaying the time for restenosis.
Clinical Significance
The approval of the malignant stenosis cryoablation system by the NMPA marks an important step forward in the treatment of airway tumors. By providing a more effective and less invasive option, the system is expected to improve outcomes and quality of life for patients with malignant airway stenosis.-Fineline Info & Tech
Leave a Reply